Michael Pace, Ph.D.

Associate Director, Global Feasibility

Michael Pace, Ph.D.

Associate Director, Global Feasibility

Dr. Michael Pace has more than 9 years of clinical research experience within the academic and CRO sectors, with an exclusive focus on global and strategic clinical trial feasibility within the last 4 years. A significant portion of his CRO experience has been dedicated to the feasibility of solid tumor and hematological malignancy trials, spanning from early phase dose escalation trials to larger phase II/III global programs. He provides extensive experience in integrating critical strategic and data elements into clinical trial strategies, including but not limited to disease background, competitive landscapes, dose cohort mapping, epidemiology, standard of care, country and region considerations, enrollment rate assessments, and recruitment projections. Dr. Pace also brings a comprehensive understanding of the constantly evolving gamut of data platforms utilized to plan clinical studies. From historical trial data to real-world evidence and patient EMR data sources, he is dedicated to providing custom, data-driven strategies for complex and challenging clinical studies.

His therapeutic expertise spans many fields and indications, including solid tumor and hematological malignancies, neurology, psychiatry, rare disease, cardiovascular, renal/metabolic disorders, dermatology and medical device.

Dr. Pace earned his Bachelor of Science in Biology and Neuroscience from Indiana University and his PhD in Biomedical Sciences from the University of Florida.

Why Oncology?

“The field of oncology has always held a significant place in my heart, and I think the hearts of many others as well, as it is nearly impossible to meet someone whose life has not been affected by one of the many forms that cancer can take. And yet, despite the detrimental impact that these diseases have on individuals and families, the communal response to support cancer research and providing resources to patients and families is one of the most inspiring parts about planning oncology studies. On top of this, my background as a scientist lends to an intellectual fascination with the medical technology being developed for patients with cancer. From CAR-T cells and novel antibody-drug conjugates to leveraging genetic and biomarker testing for precision medicine, I couldn’t imagine a more exciting time to be involved in oncology research.”

This is what drives Michael:

“During my tenure as a scientific researcher in graduate school, I spent countless hours at the lab bench attempting to understand the underlying causes of some of the most crippling diseases that impact our societies. However, throughout this process, I always felt removed from the patients that benefit from these research efforts. I felt like I was on the sidelines as many members of my family passed away from the very diseases I was researching, such as my grandfather to hepatocellular carcinoma or grandmother to Alzheimer’s disease. Shifting my career to be directly involved in the planning of clinical trials has been immensely rewarding, both personally and professionally. Bearing witness to the array of clinical research efforts put forth not only by my colleagues, but also by our clients gives me hope that fewer individuals will have to feel on the sidelines as their friends and family members continue to be affected by the diseases that our work seeks to cure.”

Content by Michael Pace, Ph.D.

michael pace
Blog Post

Ensuring Successful Enrollment in Oncology Dose Escalation Trials

Oncology dose-escalation trials are a distinct entity, with nuances and considerations which set them apart from other therapeutic areas. From varying trial designs to the patients who participate, dose-finding clinical trials in oncology are a clinical research paradigm. Understanding strategies to facilitate success is key to study planning and execution, from feasibility to site selection through enrollment and treatment.